SAB Biotherapeutics (NASDAQ:SABS) Stock Price Expected to Rise, Chardan Capital Analyst Says

SAB Biotherapeutics (NASDAQ:SABS) had its price objective raised by stock analysts at Chardan Capital from $12.00 to $14.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target indicates a potential upside of 205.01% from the stock’s previous close.

A number of other brokerages also recently issued reports on SABS. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. UBS Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price for the company. Guggenheim began coverage on shares of SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright reduced their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Trading Up 0.2%

Shares of SABS stock opened at $4.59 on Wednesday. The business’s fifty day moving average price is $4.02 and its 200 day moving average price is $3.35. The firm has a market capitalization of $233.86 million, a PE ratio of -1.98 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 10.50. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). As a group, sell-side analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently added to or reduced their stakes in SABS. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter worth about $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $34,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $40,000. Finally, State Street Corp acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $49,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.